Saarland University-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2022

  1. Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 1, pp. 100-103

  2. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 4, pp. 406-419

  3. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 1, pp. 85-99

2021

  1. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: A review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 7, Núm. 6, pp. 557-567

2020

  1. Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: Systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 6, Núm. 2, pp. 86-93

  2. Lipid management in rheumatoid arthritis: A position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 6, Núm. 2, pp. 104-114

2019

  1. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: Systematic review and meta-analysis

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 5, Núm. 4, pp. 226-236

  2. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 5, Núm. 3, pp. 171-180

2018

  1. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 4, Núm. 3, pp. 180-188

  2. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: A review

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 4, Núm. 4, pp. 230-236